T-Therapeutics Ltd.

https://www.t-therapeutics.com

LinkedIn: https://www.linkedin.com/company/t-therapeutics

T-Therapeutics is a next-generation T cell receptor (TCR) company spun off from the University of Cambridge. The company was created to harness the power of T cell biology, evolved over millions of years, to create safe and effective treatments for many cancers and autoimmune diseases. T-Therapeutics combines world-leading expertise in mouse genome engineering, deep knowledge and experience in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. T-Therapeutics is developing ‘optimal’ TCR based therapeutics using a proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs. These TCRs are directed at multiple target classes, many of which have never been worked on before. The company is developing a pipeline of first-in-class drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases. *

	Start	2022-05-10 established (s-off)
	Predecessor	University of Cambridge
	Industry	TCR engineering technology (T-cell receptor engineering technology)
	Industry 2	transgenic mouse
	Person	Bradley, Allan (Wellcome Trust 200011– Professor Sanger Institute before Howard Hughes Medical Institute)
	Person 2	Seghezzi, Graziano (Sofinnova Partners 200806 Partner)

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	3 Riverside, Suite 1 Granta Park
	City	CB21 6AD Cambridge, Cambridgeshire
		Address record changed: 2023-11-16

Basic data	Employees	n. a.

		* Document for »About Section«: T-Therapeutics Ltd.. (6/12/24). "Press Release: T-Therapeutics Appoints Dr David Hung as Chairman". Cambridge.

		Record changed: 2024-08-24